Omkar Pharmachem

Why is Omkar Pharmachem Ltd falling/rising?

As of 20-Jun, Omkar Pharmachem Ltd's stock price is at 19.00, down 2.56% and showing a significant decline of 29.63% over the past month. The stock has underperformed the market and is trading below all key moving averages, indicating a bearish trend.

As of 20-Jun, Omkar Pharmachem Ltd's stock price is currently at 19.00, reflecting a decrease of 0.5, or 2.56%. The stock has shown a significant decline over the past month, with a drop of 29.63%, while the benchmark Sensex has increased by 2.13% during the same period. Year-to-date, the stock is down 32.26%, compared to a 9.88% decline in the Sensex, indicating a substantial underperformance relative to the market.<BR><BR>Today's performance further highlights the stock's struggles, as it has underperformed its sector by 3.28%. Additionally, the stock has not traded on one day out of the last 20 days, suggesting erratic trading behavior. It is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend.<BR><BR>Despite a rise in investor participation, with a delivery volume increase of 113.59% on June 17 compared to the 5-day average, the overall sentiment remains negative. This combination of poor performance metrics, significant declines over various time frames, and underwhelming trading activity contributes to the current downward movement in Omkar Pharmachem Ltd's stock price.

Which are the latest news on Omkar Pharmachem?

What does Omkar Pharmachem do?

Omkar Pharmachem Ltd is a micro-cap company focused on pharmaceuticals and chemical products, currently providing support services with no commercial activity or net profit reported as of March 2026. The company has a market cap of INR 21 Cr and key financial metrics indicate a high P/E ratio of 157.00 and a return on equity of 0.35%.

Overview: <BR>Omkar Pharmachem Ltd is engaged in the business of pharmaceuticals and chemical products within the commodity chemicals industry, categorized as a micro-cap company.<BR><BR>History: <BR>Omkar Pharmachem Limited was incorporated on March 31, 1995. The company has not conducted any commercial activity during the year and is currently focused on providing support services related to pharmaceuticals and chemicals. The latest quarterly results reported are for March 2026, showing no net profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 21 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 157.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.01 <BR>Return on Equity: 0.35% <BR>Price to Book: 0.59<BR><BR>Contact Details: <BR>Address: 501 Mahakant Bldg Ashram Road, Opp V S Hospital Ellisbridge Ahmedabad Gujarat : 380006 <BR>Tel: 91-079-26580892 <BR>Email: investors.opl@gmail.com <BR>Website: http://www.omkarpharmachem.co.in

How big is Omkar Pharmachem?

As of 10th June, Omkar Pharmachem Ltd has a market capitalization of 21.00 Cr, with Net Sales of 0.00 Cr and a Net Profit of 0.13 Cr reported in the latest four quarters. Shareholder's Funds were valued at 9.43 Cr, and Total Assets amounted to 9.57 Cr for the annual period ending in March 2025.

As of 10th June, Omkar Pharmachem Ltd has a market capitalization of 21.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.00 Cr and a Net Profit of 0.13 Cr.<BR><BR>For the latest annual period ending in March 2025, Shareholder's Funds were valued at 9.43 Cr, while Total Assets amounted to 9.57 Cr.

Who are in the management team of Omkar Pharmachem?

The management team of Omkar Pharmachem includes Anurag Sharma (Managing Director), Parminder Sharma (Non Executive Director), Mamta Pachori (Non Executive Independent Director), Janak Raj (Non Executive Independent Director), and Pankaj Singh (Company Secretary & Compliance Officer).

The management team of Omkar Pharmachem includes the following individuals:<BR><BR>1. Anurag Sharma - Managing Director<BR>2. Parminder Sharma - Non Executive Director<BR>3. Mamta Pachori - Non Executive Independent Director<BR>4. Janak Raj - Non Executive Independent Director<BR>5. Pankaj Singh - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Omkar Pharmachem?

Omkar Pharmachem's peers include Vinyoflex, Caprolactam Chem, Tulasee Bio-Eth., Deco-Mica, Pentokey Organy, Square Four Pro., Jayshree Chem., Vivid Global, and Sreechem Resins. Tulasee Bio-Eth. has the highest 1-year return at 127.58%, while Omkar Pharmachem's return is -28.97%.

Peers: The peers of Omkar Pharmachem are Vinyoflex, Caprolactam Chem, Tulasee Bio-Eth., Deco-Mica, Pentokey Organy, Square Four Pro., Jayshree Chem., Vivid Global, and Sreechem Resins.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sreechem Resins, while Average management risk is found at Vinyoflex and Jayshree Chem., and Below Average management risk is noted at Caprolactam Chem, Deco-Mica, Pentokey Organy, and Vivid Global. Tulasee Bio-Eth. and Square Four Pro. do not qualify for management risk assessment. Growth is Below Average for Vinyoflex, Caprolactam Chem, Deco-Mica, Pentokey Organy, and Jayshree Chem., while Average growth is seen at Vivid Global. Tulasee Bio-Eth. and Square Four Pro. do not qualify for growth assessment. Capital Structure is Good for Vinyoflex, Pentokey Organy, and Vivid Global, while Below Average is noted for Caprolactam Chem, Deco-Mica, Jayshree Chem, and Sreechem Resins, with Tulasee Bio-Eth. and Square Four Pro. not qualifying.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Tulasee Bio-Eth. at 127.58%, while the lowest is Vinyoflex at -23.19%. Omkar Pharmachem's 1-year return is -28.97%, which is lower than both of these peers. Additionally, the six-month return is negative for Pentokey Organy, Deco-Mica, and Omkar Pharmachem.

When is the next results date for Omkar Pharmachem Ltd?

The next results date for Omkar Pharmachem Ltd is 30 May 2026.

The next results date for Omkar Pharmachem Ltd is scheduled for 30 May 2026.

Is Omkar Pharmachem overvalued or undervalued?

As of August 12, 2025, Omkar Pharmachem is considered very expensive and overvalued, with a PE ratio of 25.90 and a PEG ratio of 4.92, indicating its growth prospects do not justify its current price despite a strong historical return of 323.06%.

As of 12 August 2025, the valuation grade for Omkar Pharmachem has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 25.90, an EV to EBIT ratio of 26.13, and a ROCE of only 3.17%, which raises concerns about its profitability relative to its valuation.<BR><BR>In comparison to its peers, Omkar Pharmachem's valuation metrics appear less favorable. For instance, Sun Pharma has a PE ratio of 33.93, while Cipla offers a more attractive PE of 22.77. Additionally, the PEG ratio of 4.92 suggests that the company's growth prospects may not justify its current price. Despite a strong historical performance over the last decade, with a return of 323.06%, the current valuation does not align with its financial fundamentals, reinforcing the conclusion that Omkar Pharmachem is overvalued.

How has been the historical performance of Omkar Pharmachem?

Omkar Pharmachem has shown minimal financial activity, with net sales at zero since Mar'18, but has stabilized other operating income at 0.54 Cr since Mar'22. While profit metrics have gradually improved, the company still carries negative reserves, though the deficit has decreased from -1.42 Cr in Mar'21 to -0.65 Cr in Mar'25.

Answer:<BR>The historical performance of Omkar Pharmachem shows a consistent trend of minimal financial activity over the years, with net sales remaining at zero from Mar'18 to Mar'25. The company has reported other operating income of 0.54 Cr for Mar'24 and Mar'25, which is an increase from 0.27 Cr in Mar'21. Total operating income has remained stable at 0.54 Cr since Mar'22. The total expenditure, excluding depreciation, has varied slightly, with a peak of 0.27 Cr in Mar'22 and a low of 0.23 Cr in Mar'23, leading to an operating profit (PBDIT) that has fluctuated around 0.29 Cr to 0.31 Cr in recent years. Profit before tax has shown a gradual improvement, reaching 0.27 Cr in Mar'25, while profit after tax has also increased slightly to 0.20 Cr in the same period. The company has maintained a negative reserve balance, which has improved from -1.42 Cr in Mar'21 to -0.65 Cr in Mar'25. <BR><BR>Breakdown:<BR>Omkar Pharmachem's financial performance indicates a lack of significant revenue generation, with net sales consistently reported as zero over the past several years. The company has, however, managed to generate some other operating income, which has stabilized at 0.54 Cr since Mar'22, reflecting a modest increase from previous years. Total expenditure has remained relatively low, allowing for a positive operating profit that has hovered around 0.29 Cr to 0.31 Cr in the last few years. Profit before tax has shown a positive trend, reaching 0.27 Cr in Mar'25, while profit after tax has also seen slight growth, indicating some operational stability. Despite these improvements, the company continues to carry negative reserves, although there has been a gradual reduction in the deficit over the years, suggesting a potential for future recovery. Overall, the financial data reflects a company that has not yet achieved significant operational success but is showing signs of gradual improvement in profitability metrics.

What is the technical trend for Omkar Pharmachem?

As of May 12, 2025, Omkar Pharmachem shows a mildly bullish trend, supported by daily moving averages and Bollinger Bands, though caution is advised due to bearish signals from the weekly and monthly MACD and RSI.

As of 12 May 2025, the technical trend for Omkar Pharmachem has changed from does not qualify to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly and monthly MACD and RSI readings are mildly bearish. However, the Bollinger Bands are showing a mildly bullish trend on both weekly and monthly time frames. The KST is bullish on both weekly and monthly, which adds some strength to the mildly bullish outlook. Overall, the current stance is mildly bullish, but caution is advised due to the bearish signals from the MACD and RSI on the weekly and monthly charts.

Who are the top shareholders of the Omkar Pharmachem?

The top shareholders of Omkar Pharmachem include promoter Shah Kirtikumar Laxmichand with 0.02% and public shareholder Kuldeep Singh with 3.72%. Individual investors hold a significant 98.36% of the shares, with no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Omkar Pharmachem include Shah Kirtikumar Laxmichand, who is the promoter with the highest holding at 0.02%. The highest public shareholder is Kuldeep Singh, holding 3.72%. Additionally, individual investors collectively hold a significant portion, accounting for 98.36% of the shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares.

Has Omkar Pharmachem declared dividend?

No Dividend History Available